Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B

A. K. Singal, H. Salameh, Yong Fang Kuo, R. J. Fontana

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (CHB). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma (HCC) is not well described. Aim To determine the efficacy of oral anti-viral agents in reducing HCC risk in relationship with other known factors. Methods Published studies of at least 20 CHB patients treated with an oral anti-viral agent and followed for >2 years were analysed for incidence of HCC per 100 person years follow-up. Results Pooled homogeneous data from six studies showed lamivudine (LAM) treatment (n = 3306) to reduce HCC risk by 51% compared with no treatment (n = 3585) (3.3 vs. 9.7 per 100 person years, P < 0.0001). Pooled data from 49 studies (23 with LAM; 16 with adefovir; and 10 with entecavir, tenofovir or telbivudine) of 10 025 treated patients showed HCC incidence of 1.3 per 100 person years, independent of the agent used. Patient age >50 years and hepatitis B virus-DNA detectability at HCC diagnosis increased risk of HCC by twofold with a 10-fold higher risk among patients with cirrhosis compared with chronic hepatitis. Meta-regression showed patient age, study location (Eastern vs. Western) and type of study (randomised or not) contributed to heterogeneity. Conclusions Lamivudine treatment significantly reduces the incidence of HCC compared with no treatment. However, HCC still develops at a rate of 1.3 per 100 patient years in CHB patients receiving an oral anti-viral agent. This finding highlights the need for continued HCC surveillance, particularly in CHB patients with inadequate viral suppression, older age and cirrhosis.

Original languageEnglish (US)
Pages (from-to)98-106
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume38
Issue number2
DOIs
StatePublished - Jul 2013

Fingerprint

Chronic Hepatitis B
Meta-Analysis
Hepatocellular Carcinoma
Incidence
Lamivudine
Fibrosis
Reducing Agents
Chronic Hepatitis
Therapeutics
Hepatitis B virus
DNA

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Meta-analysis : The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. / Singal, A. K.; Salameh, H.; Kuo, Yong Fang; Fontana, R. J.

In: Alimentary Pharmacology and Therapeutics, Vol. 38, No. 2, 07.2013, p. 98-106.

Research output: Contribution to journalArticle

@article{2e6e4acd5c364e71b88319767a7fbc6a,
title = "Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B",
abstract = "Background Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (CHB). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma (HCC) is not well described. Aim To determine the efficacy of oral anti-viral agents in reducing HCC risk in relationship with other known factors. Methods Published studies of at least 20 CHB patients treated with an oral anti-viral agent and followed for >2 years were analysed for incidence of HCC per 100 person years follow-up. Results Pooled homogeneous data from six studies showed lamivudine (LAM) treatment (n = 3306) to reduce HCC risk by 51{\%} compared with no treatment (n = 3585) (3.3 vs. 9.7 per 100 person years, P < 0.0001). Pooled data from 49 studies (23 with LAM; 16 with adefovir; and 10 with entecavir, tenofovir or telbivudine) of 10 025 treated patients showed HCC incidence of 1.3 per 100 person years, independent of the agent used. Patient age >50 years and hepatitis B virus-DNA detectability at HCC diagnosis increased risk of HCC by twofold with a 10-fold higher risk among patients with cirrhosis compared with chronic hepatitis. Meta-regression showed patient age, study location (Eastern vs. Western) and type of study (randomised or not) contributed to heterogeneity. Conclusions Lamivudine treatment significantly reduces the incidence of HCC compared with no treatment. However, HCC still develops at a rate of 1.3 per 100 patient years in CHB patients receiving an oral anti-viral agent. This finding highlights the need for continued HCC surveillance, particularly in CHB patients with inadequate viral suppression, older age and cirrhosis.",
author = "Singal, {A. K.} and H. Salameh and Kuo, {Yong Fang} and Fontana, {R. J.}",
year = "2013",
month = "7",
doi = "10.1111/apt.12344",
language = "English (US)",
volume = "38",
pages = "98--106",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Meta-analysis

T2 - The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B

AU - Singal, A. K.

AU - Salameh, H.

AU - Kuo, Yong Fang

AU - Fontana, R. J.

PY - 2013/7

Y1 - 2013/7

N2 - Background Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (CHB). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma (HCC) is not well described. Aim To determine the efficacy of oral anti-viral agents in reducing HCC risk in relationship with other known factors. Methods Published studies of at least 20 CHB patients treated with an oral anti-viral agent and followed for >2 years were analysed for incidence of HCC per 100 person years follow-up. Results Pooled homogeneous data from six studies showed lamivudine (LAM) treatment (n = 3306) to reduce HCC risk by 51% compared with no treatment (n = 3585) (3.3 vs. 9.7 per 100 person years, P < 0.0001). Pooled data from 49 studies (23 with LAM; 16 with adefovir; and 10 with entecavir, tenofovir or telbivudine) of 10 025 treated patients showed HCC incidence of 1.3 per 100 person years, independent of the agent used. Patient age >50 years and hepatitis B virus-DNA detectability at HCC diagnosis increased risk of HCC by twofold with a 10-fold higher risk among patients with cirrhosis compared with chronic hepatitis. Meta-regression showed patient age, study location (Eastern vs. Western) and type of study (randomised or not) contributed to heterogeneity. Conclusions Lamivudine treatment significantly reduces the incidence of HCC compared with no treatment. However, HCC still develops at a rate of 1.3 per 100 patient years in CHB patients receiving an oral anti-viral agent. This finding highlights the need for continued HCC surveillance, particularly in CHB patients with inadequate viral suppression, older age and cirrhosis.

AB - Background Five oral nucleos(t)ide analogues are available to treat chronic hepatitis B (CHB). With the availability of newer agents, their efficacy on incidence of hepatocellular carcinoma (HCC) is not well described. Aim To determine the efficacy of oral anti-viral agents in reducing HCC risk in relationship with other known factors. Methods Published studies of at least 20 CHB patients treated with an oral anti-viral agent and followed for >2 years were analysed for incidence of HCC per 100 person years follow-up. Results Pooled homogeneous data from six studies showed lamivudine (LAM) treatment (n = 3306) to reduce HCC risk by 51% compared with no treatment (n = 3585) (3.3 vs. 9.7 per 100 person years, P < 0.0001). Pooled data from 49 studies (23 with LAM; 16 with adefovir; and 10 with entecavir, tenofovir or telbivudine) of 10 025 treated patients showed HCC incidence of 1.3 per 100 person years, independent of the agent used. Patient age >50 years and hepatitis B virus-DNA detectability at HCC diagnosis increased risk of HCC by twofold with a 10-fold higher risk among patients with cirrhosis compared with chronic hepatitis. Meta-regression showed patient age, study location (Eastern vs. Western) and type of study (randomised or not) contributed to heterogeneity. Conclusions Lamivudine treatment significantly reduces the incidence of HCC compared with no treatment. However, HCC still develops at a rate of 1.3 per 100 patient years in CHB patients receiving an oral anti-viral agent. This finding highlights the need for continued HCC surveillance, particularly in CHB patients with inadequate viral suppression, older age and cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=84879241608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879241608&partnerID=8YFLogxK

U2 - 10.1111/apt.12344

DO - 10.1111/apt.12344

M3 - Article

C2 - 23713520

AN - SCOPUS:84879241608

VL - 38

SP - 98

EP - 106

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -